HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
AALL1521; Ruxolitinib and Chemotherapy for Patients with JAK-Mutant B-ALL
This study is now recruiting.
This study is testing the safety and effectiveness of adding a targeted therapy (ruxolitinib) to standard chemotherapy for children, adolescents, and young adults with high-risk acute lymphoblastic leukemia with CRLF2 and other JAK pathway mutations.
Who Do I Contact?
If you are interested in participating in the study or want to learn more please contact our study team at tasians [at] chop.edu or 267-426-0762.
Eligibility & Criteria
AALL1521; A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway–Mutant Acute Lymphoblastic Leukemia (INCB 18424-269)
Eligible Age Range: